Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
Saved in:
| Title: | Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. |
|---|---|
| Authors: | Kacimi SEO; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Sorbonne Université, CinBioS, UMS 37 PASS, INSERM, Paris, France., Dehais C; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Feuvret L; Hospices Civils de Lyon, Radiotherapy Department, Bron, France., Chinot O; Department of Neuro-Oncology, Aix-Marseille Université, CHU Timone, AP-HM, Marseille, France., Carpentier C; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France., Bronnimann C; Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France., Vauleon E; Centre Eugène Marquis, Medical Oncology, INSERM U1242, University of Rennes, Rennes, France., Djelad A; Department of Neurosurgery, University Hospital of Lille, Lille, France., Cohen-Jonathan Moyal E; Department of Radiation Oncology, Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.; Institut National de la Santé et de la Recherche Médicale U1037, Centre de Recherche contre le Cancer de Toulouse, Toulouse, France.; Université Toulouse III Paul Sabatier, Toulouse, France., Langlois O; Department of Neurosurgery, University Hospital of Rouen, Rouen, France., Campone M; Institut de Cancérologie de l'Ouest-René Gauducheau, Centre de Recherche en Cancérologie, Saint Herblain, France., Ducloie M; Department of Neurology, CHU de Caen Normandie, Caen, France., Noel G; Radiation Oncology Department, Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, France.; Radiobiology Laboratory, Centre Paul Strauss, IIMIS - Imagerie Multimodale Integrative en Santé, ICube, Strasbourg University, Strasbourg, France., Cuzzubbo S; Neurology Department, APHP, University Hospital Saint Louis, Paris, France.; Université Paris Cité, Paris, France., Taillandier L; Neurology Department, CHU de Nancy, Nancy, France., Ramirez C; Neurology Department, North Hospital, University Hospital of Saint Etienne, Saint-Priest-en-Jarez, France., Younan N; Neurology Department, Hôpital Foch, Suresnes, France., Menei P; Neurosurgery Department, CHU Angers, Angers, France., Dhermain F; Radiotherapy Department, Institut Gustave Roussy, Villejuif, France., Desenclos C; Neurosurgery Department, Hôpital Nord, CHU Amiens, Amiens, France., Ghiringhelli F; Centre Georges-François Leclerc, Medical Oncology, Dijon, France., Bourg V; Neurology Department, CHU Nice, Nice, France., Ricard D; Neurology department, Hôpital National d'Instruction des Armées Percy, Service de Santé des Armées, Clamart, France., Faillot T; Neurosurgery Department, AP-HP, Hôpital Beaujon, Clichy, France., Appay R; Department of Pathology and Neuropathology, Aix-Marseille University, CHU Timone, AP-HM, Marseille, France., Tabouret E; Department of Neuro-Oncology, Aix-Marseille Université, CHU Timone, AP-HM, Marseille, France., Nichelli L; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuroradiologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Mathon B; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neurochirurgie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Thomas A; Service de Radiothérapie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Tran S; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuropathologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Bielle F; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuropathologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Alentorn A; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Iorgulescu JB; Molecular Diagnostics Laboratory, Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Boëlle PY; Sorbonne Université, CinBioS, UMS 37 PASS, INSERM, Paris, France., Labreche K; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Sorbonne Université, CinBioS, UMS 37 PASS, INSERM, Paris, France., Hoang-Xuan K; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Sanson M; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Idbaih A; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France., Figarella-Branger D; Department of Pathology and Neuropathology, Aix-Marseille University, CHU Timone, AP-HM, Marseille, France., Ducray F; Neuro-Oncology Unit, Hospices Civils de Lyon, Lyon, France.; LabEx Dev2CAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Université de Lyon, Université Claude Bernard, Villeurbanne, France., Touat M; Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.; Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France.; Department of Neurology, Brigham and Women's Hospital, Boston, MA. |
| Corporate Authors: | POLA Network |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Jan 20; Vol. 43 (3), pp. 329-338. Date of Electronic Publication: 2024 Oct 02. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
